Fibrocell has entered into exclusive channel collaborations (ECCs) with Intrexon Corporation (NYSE: XON), a leader in synthetic biology, to facilitate the assembly and delivery of the necessary target gene constructs for delivery to autologous fibroblasts. Access to Intrexon’s technology platform allows Fibrocell a rapid method to screen and construct the best genetic therapeutic solutions.
In certain therapeutic applications, Fibrocell will use Intrexon’s proprietary RheoSwitch Therapeutic System® (RTS®) technology. The RTS biologic switch is activated by an orally-administered compound that provides the ability to control level and timing of protein expression in those diseases where such control is ideal.
Fibrocell has teamed with scientists at the University of California, Los Angeles (UCLA) to discover a media supplement that contributes to the genomic stability of induced pluripotent stem cells (iPSCs) while growing in culture. Issues common to genomic stability with iPSC culture have prevented significant advance into clinical trials. This media supplement may allow for advancement of this technology.
Fibrocell welcomes discussion with pharmaceutical, academic and government organizations that share the company’s vision and can bring assets that complement its development strategies. Interested parties should contact Fibrocell at 484.713.6000 or send a non-confidential email.